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Diabetes is associated with disturbances in the normal levels of both insulin and glucagon, both of which
play critical roles in the regulation of glycemia. Recent studies have found lipocalin-type prostaglandin
D2 synthase (L-PGDS) to be an emerging target involved in the pathogenesis of type-2 diabetes. This study
focused on the effect of L-PGDS on glucagon secretion from cultured pancreatic Alpha TC-1 Clone 6 cells.
When cells were treated with various concentrations of L-PGDS (0, 10, 50, and 100 ug/ml) for 2 h in 1 mM
glucose; glucagon secretion decreased to 670745, 838738, 479711, and 437745 pg/ml, respectively.
In addition, pancreatic islets were isolated from C57BL/6 mice and stained for prostaglandin D2 receptors,
DP1 and DP2, using immunohistochemistry. Our results showed that these islets express only the DP1
receptor. Pancreatic islets were then stained for alpha and beta cells, as well as DP1, to ﬁnd the primary
location of the receptor within the islets using immunoﬂuorescence. Interestingly, DP1 receptor density
was found primarily in alpha cells rather than in beta cells. Our study is the ﬁrst to report a correlation
between L-PGDS and glucagon secretion in alpha cells. Based on our obtained results, it can be concluded
that higher concentrations of L-PGDS signiﬁcantly reduced the secretion of glucagon in alpha cells, which
may contribute to the pathogenesis of diabetes as well as offer a novel therapeutic site for the treatment
of diabetes.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lipocalin-type prostaglandin D2 synthase (L-PGDS) is the en-
zyme which plays an important role in the metabolism of ara-
chidonic acid by converting PGH2 into PGD2. PGD2 gets converted
into numerous prostaglandins including and 15-deoxy-D12, 14-
PGJ2 (15d-PGJ2) [1,2]. PGD2 is primarily produced in mast cells
and in smooth muscle cells with a synthetic phenotype [3] which
has also been reported for its accumulation during atherosclerotic
lesion formation, suggesting their strong involvement in the pa-
thogenesis of cardiovascular injuries [4]. Current literature has also
shown a strong correlation between vascular injuries and diabetes.
Brieﬂy, diabetes mellitus is the result of imbalance of normal levels
of both insulin and glucagon with their opposite effects on gly-
caemia as well as on the metabolism of nutrients. Insulin acts
mainly on muscle, liver and adipose tissue with an anabolic effect,
inducing the uptake of glucose into these tissues and its accu-
mulation as glycogen and fat, while glucagon activates liverB.V. This is an open access article u
ool of Medicine, Biomedical
n Plaza North, Suite 505-B,
a).glycogenolysis and gluconeogenesis due to its catabolic effect
which leads to increase blood glucose level [5]. Glucagon is se-
creted in response to hypoglycemia and is inhibited already when
the glucose concentration reaches 4–6 mmol/l [6,7]. Abnormal
function of alpha cells due to hyper secretion of glucagon may lead
to dysregulation of glucose homeostasis and eventually diabetes
mellitus [7]. Even though, it is a well known fact that hypergly-
cemia in diabetes is primarily due to insufﬁcient or no secretion of
insulin. However, there are ample evidences which support the
phenomenon that hyper secretion of glucagon plays very im-
portant role in initiating and maintaining hyperglycemic condi-
tions in diabetic animals and humans [8,9]. Therefore, the concept
of glucagon signaling is becoming the emerging target for the
treatment of hyperglycemia [9,10]. The condition of hypergluca-
gonemia in diabetes can be mitigated but not normalized com-
pletely by the insulin treatment [11]. The actual mechanism which
causes hyperglucagonemia has not been fully studied yet.
Therefore, a novel concept for the inhibition of glucagon needs
to be introduced. Interestingly, we found a novel enzyme, L-PGDS
which can inhibit glucagon secretion. Increased plasma glucagon
levels relative to insulin can be a determinant in the higher rate of
hepatic glucose output, which seems to be critical in maintaining
hyperglycemia in diabetic patients [12]. Recent studies have foundnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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emerging target involved in the pathogenesis of diabetes, espe-
cially type-II diabetes [13]. Therefore, we hypothesized that L-PGDS
may have a role in the regulation of glucagon from alpha cells of
pancreas and represent a future target for the development of
antidiabetic drugs.2. Materials and methods
2.1. Cell culture
Alpha TC-1 Clone 6 cells (ATCC), an pancreatic alpha cell line
isolated from C57BL/6 mice, at passage ﬁve were incubated at
37 °C and 5% CO2 in low-glucose (5.5 mM) DMEM, supplemented
with 15 mM HEPES, 0.1 mM non-essential amino acids, and
0.1 mM bovine serum albumin until glucagon extraction
procedures.
2.2. Glucagon extraction
Overnight, incubating medium was replaced with a high glu-
cose (20 mM) DMEM medium. The following day, high glucose
DMEM was removed and cells were washed twice with glucose-
free ringer's buffer. The cells were then supplemented with ring-
er's buffer containing various lower concentrations of glucose (0.5,
1, 5, and 16.5 mM) to induce secretion and incubated for 2 h. The
cells used were disposed off. The buffer collected was then ana-
lyzed for glucagon concentration released using a multiplex kit
(Millipore). After observation that lower concentrations of glucose
induce secretion, 1 mM was chosen as a baseline glucose con-
centration for experimentation with L-PGDS. Addition of L-PGDS to
the culture was used to shift the equilibrium of the PG H2 sub-
strate pool towards PG D2 and ensure a more physiological re-
sponse. Using the same extraction procedure, a new set of alpha
cells were supplemented with various concentrations (0, 10, 50,
100 μg/ml) of L-PGDS in 1 mM glucose. The buffer was then col-
lected and analyzed for glucagon concentration.
2.3. Immunohistochemistry
Histology slides with 4 μm sections of pancreas from C57BL/6
mice were washed and deparafﬁnized. The sections were then
blocked with hydrogen peroxide for 10 min and then washed in
1 TBSTþ0.05% Tween. To perform antigen retrieval, slides were
then submerged in 10 mM citric acid buffer (pH6þ0.05% Tween)
and heated to just below boiling for 20 min, then and washed in
TBST and were left to cool down at room temperature. Slides were
then given a protein block (Abcam) and incubated for 5 min at
room temperature and then washed. The slides that were desig-
nated to receive antibody received a 1:100 concentration of DP1
polyclonal antibody from rabbit (Cayman) in TBST and normal goat
serum and incubated at room temperature in a humidiﬁed
chamber for 2 h and 15 min. From this point on, control slides
were treated separately to avoid contamination. Sections were
covered with biotinylated goat-anti-rabbit lgG(HþL) (Abcam) and
incubated for 10 min at room temperature, then were washed and
covered with drops of streptavidin peroxidase (Abcam) and in-
cubated for 10 min at room temperature. All slides then received a
solution of diaminobenzidine (DAB) chromagen (Abcam) and left
for 10 min to stain. Slides were then washed and treated with
hematoxolyn, rinsed with tap water, and mounted for observation.
2.4. Immunoﬂuorescence
New slides with sections of pancreas were deparafﬁnized andgiven the same antigen retrieval protocol as in the im-
munohistochemistry procedure. Slides were then blocked in 5%
donkey serum in PBS with 0.3% triton for 1 h at room temperature
and then aspirated without rinsing. Primary antibodies were then
combined into a cocktail into a 1:100 solution in PBS (0.3% triton).
Primary antibodies included insulin (guinea pig) and glucagon
(rabbit) on one slide, and DP1 (rabbit) on another. Sections were
covered with primary antibody solution and incubated overnight
at 4 °C. The following day, slides were rinsed three times for ﬁve
minutes each in PBS (0.3% triton). A cocktail of secondary anti-
bodies in a 1:250 was made in PBS (0.3% triton) and applied to
sections and left to incubate in the dark at room temperature. The
secondary antibodies included Anti-Guinea Pig Cy3 (red) and Anti-
Rabbit FitC (green). The slides were then washed and mounted
with DAPI (blue) mounting medium for observation.
2.5. Statistical analysis
All glucagon extractions were performed twice in triplicate. The
results were analyzed using Sigma Stat for standard error and a
Student t-test was performed to determine statistical signiﬁcance
at the [po0.05].3. Results
3.1. Effect of glucose on glucagon secretion
To determine the effect of glucose on glucagon secretion using
various concentrations, we extracted the glucagon from the buffer
and measured using milliplex kit. We measured the glucagon le-
vels and compared with non glucose treated cells extraction.
Glucagon level with no glucose was found to be 961714 pg/ml
while glucagon concentrations decreased as glucose concentra-
tions were increased and found to 912710, 916710, 89073 and
801715 pg/ml with glucose concentrations of 0.5, 1, 5, 16.5 mM
respectively as shown in Fig. 1A. Based on the obtained results, as
the glucose concentrations were increased, glucagon secretion was
decreased.
3.2. Effect of L-PGDS on glucagon secretion
To determine the effect of L-PGDS on glucagon secretion, Alpha
TC1 clone 6 cells were pretreated with 1 mM glucose concentra-
tion followed by the 2 h treatment with various concentrations of
L-PGDS. The average concentrations of glucagon secretion were
found to be 670745, 838738, 479711, and 437745 pg/ml from
the respective concentrations of L-PGDS (0, 10, 50, and 100 mg/ml)
as shown in Fig. 1B. Based on the obtained results, it can be stated
that higher concentrations of L-PGDS reduce the glucagon
secretion.
3.3. Immunoﬂuorescent staining of pancreatic islets to determine the
location of DP1 receptor in alpha and beta cells
Pancreatic islets were isolated from C57BL/6 mice and stained
for prostaglandin D2 receptors both DP1 and DP2 using im-
munohistochemistry to conﬁrm that islets used in the study have
alpha cells. As shown in Fig. 2, Nuclei were stained blue with DAPI
mounting medium on the left panel. Islets were also stained for
insulin (Cy-3, red) and glucagon (FIT-C, green) to distinguish be-
tween alpha and beta cells. Islets were also stained for DP1 and
DP2 receptors (FIT-C, green) as shown on the right panel of Fig. 2.
However, this observation conﬁrmed the location of only DP1 re-
ceptor but not the DP2 receptor (data not shown) in these islets
cells.
Fig. 1. (A) Treatment of Alpha TC1 Clone 6 cells with glucose concentration. Alpha
cells treatment with supplementation of four different concentrations of glucose
(0.5,1,5 and 16.5 mM) using Alpha TC1 Clone 6 cells over the period of 2 h and
Glucagon secretion was measured. Data are expressed as Mean7SEM and statistical
analysis was performed using t-test with the signiﬁcance of po0.05. As shown
above, glucagon secretion decreases, glucose concentrations increases. (B)-Treatment
of Alpha TC1 Clone 6 cells with L-PGDS. Alpha TC1 Clone 6 cells were treated with
different concentrations of L-PGDS (0, 10, 50 and 100 mg/ml) over the period of 2 h
and Glucagon secretion was measured. Data are expressed as Mean7SEM and sta-
tistical analysis was performed using t-test with the signiﬁcance of po0.05. As
shown above, at lower concentrations, glucagon secretion increases; however, it
decreases as the L-PGDS concentrations increases. Data are expressed as Mean7SEM
and statistical analysis was performed using t-test with the signiﬁcance of po0.05.
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Immunohistochemistry was performed to show the difference
between with or without primary antibody for DP1 receptor. As
shown in Fig. 3, two different pancreatic were isolated from theFig. 2. Immunoﬂuorescent staining of pancreatic islets for DP1 receptor as well as insulin
mouse. Nuclei are stained blue with DAPI mounting medium. (A) Islet stained for insulin
(B) Islet stained for DP1 receptor (FIT-C, green). Image 2B displays very punctate staining
the periphery of the islet. Islets were also stained for DP2 receptor but there was no exislets of the same C57BL/6 mouse. (A) Without primary antibody
(B) Islet with primary antibody for DP1 receptor. In image B, there
was a clear background staining throughout most of the islet,
however, speciﬁc staining occurred in the periphery of the islet
cells, shown in dark brown.4. Discussion
Increased secretion of glucagon contributes to the dysregula-
tion of glucose homeostasis in diabetes [7]. Even though, it is a
well known fact that hyperglycemia in diabetes is mainly due to
insufﬁcient or no secretion of insulin. However, there are ample
evidences which support the phenomenon that hyper secretion of
glucagon plays very important role in initiating and maintaining
hyperglycemic conditions in diabetic animals and humans [8,9].
Therefore the concept of glucagon signaling has been considered
as an important target in the treatment of hyperglycemia [9,10].
Glucagon concentrations in diabetes can be reduced but not
completely normalized by the insulin treatment [11] and more-
over, the actual cause of underlying the hyperglucagonemia have
not been fully elaborated yet. Therefore, a novel concept for the
inhibition of glucagon needs to be introduced.
Our study is the ﬁrst to report an interesting correlation be-
tween L-PGDS and glucagon secretion in alpha cells (Alpha TC1
Clone 6) derived from C57BL/6 mice. First of all, pancreatic islets
were isolated from C57BL/6 mice and stained for DP1/DP2 receptor
as well as alpha and beta cells using immunohistochemistry which
conﬁrmed the expression of only DP1 receptor not the DP2 re-
ceptor (data not shown) in alpha cells not in beta cells as shown in
Fig. 2 where nuclei are stained blue with DAPI mounting medium
on the left panel. Islets were also stained for insulin (Cy-3, red) and
glucagon (FIT-C, green) to distinguish between alpha and beta
cells. Islets were also stained for DP1 receptor (FIT-C, green) as
shown on the right panel of Fig. 2. Islets were also stained for DP2
receptor but there was no expression observed (data not shown).
This observation conﬁrmed that isolated islets have alpha cells.
Since it is a well know concept that prostaglandin D2 acts through
DP1 and DP2 receptor [14]. As shown in Fig. 3, alpha cells were
compared with and without primary antibody for DP1 receptor
and interestingly these cells expressed only DP1 receptor which
can be clearly distinguished between left (A) and right panel
of Fig. 3B. After the conﬁrmatory studies of alpha cells, alpha TC-1and glucagon. Two different pancreatic islets were isolated from the same C57BL/6
(Cy-3, red) and glucagon (FIT-C, green) to distinguish between alpha and beta cells.
throughout the islet; however, the stain shows a tendency of cluster formation on
pression observed (data not shown).
Fig. 3. Immunohistochemistry: Unstained and stained pancreatic islets for DP1 receptor. Two different pancreatic islets isolated from the same C57BL/6 mouse. (A) without
primary antibody treated islets. (B) Primary antibody treated Islets for DP1 receptor. In image B, there is clear background staining throughout most of the islet, however,
speciﬁc staining occurs in the cells in the periphery of the islet, shown in dark brown.
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were cultured in high glucose (20 mM) DMEM medium overnight.
The following day, the media was replaced with various lower
concentrations of glucose (0.5, 1, 5, and 16.5 mM) for 2 h to induce
secretion. Glucagon concentrations measured were found to be
912710, 916711, 89073 and 801715 with treatment of 0.5, 1, 5,
and 16.5 mM glucose respectively. Our results conﬁrmed that
lower concentrations of glucose cause the cells to secrete more
glucagon as shown in Fig. 1A which is consistent with the existing
literature [6,15] and 1 mM glucose concentration was chosen for
further experiments. Cells were then treated with various con-
centrations (0, 10, 50, and 100 mg/ml) of L-PGDS for 2 h in 1 mM
glucose; glucagon secretion was then measured using a Millipore
Milliplex kit. High concentrations of L-PGDS were found to reduce
the amount of glucagon secretion into the media. The average
concentrations of glucagon secretion were found to be 670745,
838738, 479711, and 437745 pg/ml from the respective con-
centrations of L-PGDS (0, 10, 50, and 100 mg/ml). This showed an
increase in basal glucagon secretion with a supplementation of a
low concentration of L-PGDS (10 pg/ml) and an immediate drop
below basal at high concentrations as shown in Fig. 1B.
Based on the obtained results, it can be concluded that islets
isolated from the mice had alpha cells conﬁrmed by immuno-
ﬂuorescence and immunohistochemistry. Moreover, alpha cells
expressed only DP1 receptor which can be clearly seen in Fig. 2
and also been conﬁrmed using with and without primary antibody
for DP1 and found clear presence of DP1 receptor on the right
panel as shown in Fig. 3B. Collectively it can be stated that higher
concentrations of L-PGDS reduced the glucagon secretion from
alpha cells which was possibly mediated through DP1 receptor. It
could be more interesting to measure the PGD2 production in the
alpha cells but due to immediate non-enzymatic conversion of
PGD2 into PGJ2 was found to be more challenging. Further studies
need to be performed to elucidate the exact mechanism of action
using diabetic animal model which is under progress.Acknowledgments
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